Drug Design, Development and Therapy

Dovepress
Taylor & Francis Group

Open Access Full Text Article

REVIEW

Dexmedetomidine Dosing Strategies in Sedation and Anesthesia: Pharmacokinetics, Safety, and Clinical Applications — A Narrative Review

Yung-Fong Tsai[1,2], Tsung-Hsiao Shih[2,3], Jyu-Shiou Ho[4,*], Shao-Chun Wu[2,3,*]

[1]Department of Anesthesiology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; [2]College of Medicine, Chang Gung University, Taoyuan, Taiwan; [3]Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; [4]Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

*These authors contributed equally to this work

Correspondence: Shao-Chun Wu, Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, No. 123, Dapi Road, Niaosong Dist, Kaohsiung, 833, Taiwan, Tel +886-7-7317123 ext. 5041, Email shaochunwu@gmail.com; sean1207@cgmh.org.tw

Background: Dexmedetomidine (DEX), a highly selective α2-adrenoceptor agonist, may produce arousable sedation through locus coeruleus–mediated noradrenergic suppression while preserving respiratory drive. Its clinical applications have expanded beyond intensive care unit (ICU) sedation to procedural sedation, anesthesia adjunction, and non-operating room settings. However, substantial heterogeneity in dosing regimens has impeded the formulation of standardized clinical protocols.

Objective: This narrative review synthesizes evidence identified through a MeSH-based search of PubMed, Embase, and the Cochrane Library (January 2020–Dec 2025), supplemented by chain referencing of foundational earlier studies, to evaluate dexmedetomidine dosing strategies, pharmacokinetics, safety, comparative efficacy, combination regimens, non-intravenous routes, and special-population considerations across sedation and anesthesia contexts.

Results: Reported bolus doses span a 60-fold range (0.05–3 μg/kg). In adults, doses of 0.25–0.5 μg/kg over 10 minutes appear to provide adequate procedural sedation with acceptable hemodynamic effects; pediatric studies report success rates exceeding 90% at 2 μg/kg. Dose-dependent bradycardia and hypotension are common but generally transient. Compared with propofol, DEX has been associated with more favorable respiratory stability but slower onset and recovery. Compared with conventional sedatives (primarily midazolam), DEX has been associated with lower delirium incidence and shorter mechanical ventilation duration in selected ICU trials, although these findings derive from heterogeneous study designs. Individual trials have reported opioid-sparing effects of up to 60%, though generalizability requires confirmation. Combination regimens with ketamine or propofol may offer synergistic benefits. Intranasal and subcutaneous routes provide non-invasive alternatives, particularly in pediatric practice. Special populations—including neonates, patients with cardiorespiratory morbidities, and obese patients—require population-specific dosing adjustments.

Conclusion: The available evidence suggests that dexmedetomidine offers a generally favorable safety profile across sedation and anesthesia contexts. However, conclusions are limited by dosing heterogeneity, small sample sizes, inconsistent outcome definitions, and absent long-term safety data. Standardized multicenter trials with uniform outcome criteria are needed to establish definitive dosing recommendations.

Keywords: dexmedetomidine, sedation, pharmacokinetics, target-controlled infusion, pediatric anesthesia, critical care

Introduction

Dexmedetomidine, a highly selective full agonist at α2-adrenoceptors, was initially approved by the U.S. Food and Drug Administration in 1999 for short-term sedation of mechanically ventilated adults in the ICU and subsequently extended in 2008 to non-intubated patients requiring procedural sedation.[1] Over the ensuing decades, this expansion has been largely attributed to its pharmacodynamic profile—characterized by sedation with preserved arousability, anxiolysis, and

https://doi.org/10.2147/DDDT.S606156
Received: 9 March 2026
Accepted: 14 May 2026
Published: 28 May 2026

analgesic properties—combined with a relatively low incidence of clinically significant respiratory depression reported across multiple randomized controlled trials and observational studies.[1,2]

Despite the rapid adoption of dexmedetomidine across clinical disciplines, significant variability persists in bolus dosing regimens, infusion rates, lockout intervals for patient-controlled sedation, adjunctive medication strategies, and monitoring standards.[3] The literature reports bolus doses spanning a 60-fold range (0.05–3 μg/kg), with wide discrepancy in administration speed (5-second rapid bolus to 30-minute loading infusion), reflecting divergent clinical practices and underscoring the absence of universally accepted protocols.[4] This review aims to synthesize the available evidence across these domains, providing clinicians with an integrated framework for understanding dexmedetomidine dosing strategies while acknowledging the inherent limitations of a narrative synthesis of heterogeneous data.

The development of sedative pharmacology progressed from long-acting barbiturates through benzodiazepines to shorter-acting agents such as propofol and midazolam, each generation defined by improved recovery profiles but persistent limitations including respiratory depression, paradoxical excitation, and hemodynamic instability.[5] DEX addressed a recognized clinical need by offering arousable sedation with comparatively less respiratory compromise, although the degree of this advantage varies across clinical contexts and patient populations. In a Cochrane systematic review and network meta-analysis, DEX was associated with reduction in mechanical ventilation duration by a mean of 1.85 days and ICU length of stay by 1.26 days relative to midazolam, while significantly decreasing delirium incidence[6,7]—findings that have informed, though not uniformly determined, contemporary ICU sedation guideline recommendations.

A structured literature search was conducted in PubMed/MEDLINE, Embase, and the Cochrane Library from January 1, 2020, through Dec 31, 2025, using the following Medical Subject Headings (MeSH) terms and Boolean strategy: ("Dexmedetomidine"[MeSH]) AND ("Conscious Sedation"[MeSH] OR "Deep Sedation"[MeSH] OR "Anesthesia"[MeSH]). The search was restricted to English-language publications involving human subjects. Foundational and historically influential studies published prior to 2020 were identified through backward citation tracking (chain referencing) of included articles, relevant systematic reviews, and clinical practice guidelines, thereby ensuring that seminal pharmacokinetic, pharmacodynamic, and dosing investigations were captured despite falling outside the primary search window. Retrieved records were independently screened by title and abstract, followed by full-text review for eligibility. Studies were included if they reported original clinical dosing data (bolus dose, infusion rate, or target-controlled infusion parameters), pharmacokinetic or pharmacodynamic parameters, or safety and efficacy outcomes for dexmedetomidine in sedation or anesthesia contexts. Comparative studies evaluating dexmedetomidine against conventional sedative–anesthetic agents—including propofol, midazolam, sevoflurane, and desflurane—were specifically sought. Case reports involving fewer than five patients were excluded. Both randomized controlled trials and observational studies (prospective and retrospective) were included given the heterogeneous nature of the available evidence base. No formal risk-of-bias assessment was performed, consistent with the narrative review methodology.

While several previous narrative reviews and meta-analyses have addressed specific aspects of dexmedetomidine pharmacology, the present review is distinguished by its integrated, cross-population synthesis of bolus dosing strategies, TCI model selection, and combination regimen optimization—areas that remain fragmented in the existing literature. Despite the advantages noted above, dexmedetomidine is not without limitations. Dose-dependent bradycardia and hypotension remain clinically significant concerns, recovery times are generally longer than those of propofol, the evidence for several clinical applications derives from small, heterogeneous studies, and long-term safety data—particularly regarding neurodevelopmental outcomes in pediatric populations—are lacking.

Pharmacological Basis and Mechanism of Action

DEX exerts its primary sedative and anxiolytic effects through agonism at α2-adrenoceptors in the locus coeruleus, the principal noradrenergic nucleus in the brainstem.[8,9] Receptor activation suppresses norepinephrine release, reduces neuronal excitability,[8,10] and produces a sedation state that closely mimics natural non-REM sleep,[10] distinguished by preserved arousability and intact airway protective reflexes.[11] Unlike propofol and benzodiazepines, which enhance inhibitory GABA-ergic tone throughout the cortex, DEX does not cause the respiratory depression characteristic of those agents at clinically relevant doses.[11,12]

Peripheral α2-receptor activation mediates sympatholysis, resulting in reductions in plasma catecholamine concentrations, attenuation of the hemodynamic stress response to surgical stimuli, and consequent stabilization of heart rate and blood pressure.[4,10,13] The biphasic hemodynamic response to rapid DEX administration—initial transient hypertension from peripheral α2B-receptor–mediated vasoconstriction, followed by sustained hypotension and bradycardia from central sympatholysis—is an important pharmacodynamic characteristic that informs recommended administration rates and dose titration strategies.[10,13]

Spinal cord dorsal horn α2-receptor agonism inhibits nociceptive signal transmission, contributing to the fundamental analgesic properties of dexmedetomidine.[10] Clinically, this mechanism translates to a significant opioid-sparing effect, with meta-analytic evidence demonstrating its capacity to substantially reduce postoperative opioid requirements in abdominal surgery.[14] Additionally, DEX exhibits neuroprotective properties through inhibition of NF-κB–mediated inflammatory signaling,[15] suppression of neuronal apoptosis via PI3K/Akt pathway activation,[16] attenuation of NLRP3 inflammasome–driven pyroptosis,[17] and downregulation of hippocampal c-fos and relaxin-3 expression, thereby mitigating neuronal hyperexcitability and potentially preserving cognitive performance.[18] These mechanisms may contribute to reducing postoperative cognitive dysfunction, particularly in older patients.

Furthermore, the pharmacodynamic profile of dexmedetomidine exhibits sex-specific variations. During laryngeal mask airway (LMA) insertion with a 0.5 μg/kg dexmedetomidine adjunct, male patients necessitate a significantly higher propofol effect-site concentration (Ce50: 5.46 ± 0.26 μg/mL) than females (3.82 ± 0.34 μg/mL). This disparity suggests that inherent sex differences in α2-receptor sensitivity can substantially alter combined sedative requirements.[19]

Pharmacokinetics and Pharmacodynamics

Standard Pharmacokinetic Parameters

DEX follows a two-compartment open pharmacokinetic model. The distribution half-life is approximately 6 minutes, and the elimination half-life is approximately 2 hours.[13] Protein binding is approximately 94%, predominantly to albumin and α1-acid glycoprotein. Hepatic metabolism via glucuronidation and hydroxylation generates pharmacologically inactive metabolites excreted primarily in urine (~95%).[10] The rapid distribution phase underlies the swift sedation onset observed with bolus administration, while the elimination half-life governs recovery duration. The median effective dose (ED50) for bolus dexmedetomidine in adults undergoing general anesthesia has been identified at approximately 0.25–0.28 μg/kg with favorable hemodynamic outcomes.[4] In children, the ED50 for rapid bolus administration under anesthesia was established at approximately 0.49 μg/kg.[20] These dose-finding data provide empirical anchors for clinical dosing protocols.

Target-Controlled Infusion

TCI enables precise targeting of dexmedetomidine plasma (Cp) or effect-site (Ce) concentrations via microprocessor-driven multi-compartment pharmacokinetic (PK) models, achieving moderate sedation at approximately 0.89 ng/mL and deep sedation at approximately 1.19 ng/mL during spinal anesthesia.[21] Three principal PK models have been developed, each with distinct structural assumptions and clinical implications.

Pharmacokinetic Model Parameters

The Dyck (1993) model, derived from healthy male volunteers using a three-compartment mammillary structure, established a central volume of distribution (V1) of 7.99 L, with height as the primary covariate for elimination clearance.[22] The Hannivoort (2015) model was purpose-built for TCI front-end precision, using arterial sampling and allometric weight-based scaling to yield a small V1 of 1.78 L/70 kg—a value that physiologically reflects true peak systemic concentrations before peripheral equilibration.[23] The Morse Universal (2020) model pooled data spanning neonates to elderly obese adults and offers demographic breadth, but its reliance on venous sampling in adult cohorts artificially inflates V1 to 25.2 L/70 kg.[24] Key parameters across models are summarized in Table 1 and Figure 1.

Loading Dose Safety and Clinical Implications

The V1 disparity between models has direct patient safety consequences. In plasma-targeted TCI, the initial loading dose equals V1 multiplied by the target Cp; for a target of 1 ng/mL in a 70 kg patient, the Hannivoort model delivers a safe

Table 1 Comparative Pharmacokinetic Parameters of Three Dexmedetomidine Models Standardized to 70 Kg

PK Parameter (Standardized to 70 kg)	Dyck (1993)[22]	Hannivoort (2015)[23]	Morse Universal (2020)[24]
Central Volume V1 (L)	7.99	1.78	25.2
Shallow Peripheral Volume V2 (L)	13.8	30.3	34.4
Deep Peripheral Volume V3 (L)	187.0	52.0	65.4
Elimination Clearance CL (L/min)	0.445	0.686	0.900
Intercompartmental Clearance Q2 (L/min)	2.08	2.98	1.68
Intercompartmental Clearance Q3 (L/min)	1.99	0.602	0.620
Primary Covariates	Height	Total Body Weight	FFM (CL); NFM (V)
Blood Sampling Method	Arterial	Arterial	Mixed (Arterial + Venous)

Abbreviations: FFM, fat-free mass; NFM, normal fat mass; CL, elimination clearance; V, volume of distribution.

1.78 μg bolus, while the Morse model demands 25.2 μg—exceeding the recommended 6 μg/kg/h infusion rate limit by more than threefold.[25] This supra-therapeutic surge activates postsynaptic α2B-adrenoceptors on vascular smooth muscle, precipitating acute hypertension followed by severe reflex bradycardia. The biphasic hemodynamic response has distinct EC50 thresholds: the hypertensive EC50 substantially exceeds that of the hypotensive effect, creating a narrow therapeutic window that demands careful titration.[5] Meta-analytic evidence confirms that dexmedetomidine carries a significant bradycardia risk (RR=1.88 or OR=2.38) in ICU sedation contexts,[6,26] underscoring the need for vigilant cardiovascular monitoring throughout TCI administration.



Figure 1 Loading dose safety comparison of three dexmedetomidine target-controlled infusion pharmacokinetic models. All parameters standardized to 70 kg. Loading dose = V1 × target plasma concentration (Cp). TCI sedation targets: moderate ~0.89 ng/mL; deep ~1.19 ng/mL. The horizontal bar chart (top) illustrates the central volume of distribution (V1) for each model, with the red dashed line indicating the SmPC maximum infusion rate limit (6 μg/kg/h). Safety assessment cards (middle) classify each model's loading dose relative to the SmPC threshold. Key differentiators (bottom) summarize blood sampling method, source population, primary covariates, and external validation status. See Table 1 for complete pharmacokinetic parameters.

https://doi.org/10.2147/DDDT.S606156

Pharmacodynamic Confounders

Dexmedetomidine's cooperative sedation profile introduces a clinically important pharmacodynamic confounder. Physical stimulation—such as the arousal elicited during a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) assessment—transiently increases the Ce50 for sedation by approximately 170%, rendering a previously adequate static Ce target insufficient.[27] Ambient noise further modulates baseline sensitivity: paradoxically, noise-canceling environments increase the Ce requirement by approximately 32% compared with standard procedural noise exposure, as discrete auditory stimuli are more clearly perceived against a silent background, thereby increasing patient arousability.[27] Consequently, a fixed Ce target cannot uniformly maintain adequate sedation across varying stimulation levels, and real-time upward titration must be anticipated during periods of heightened procedural activity.

Clinical Recommendations

Based on the available pharmacokinetic evidence, the Hannivoort model appears to offer a favorable safety profile for TCI deployment, as its relatively small V1 naturally constrains initial loading doses within recommended infusion-rate limits. However, it should be noted that external validation of this model across diverse clinical populations and procedural settings remains limited, and real-world implementation may introduce variability related to pump hardware, patient positioning, concurrent medications, and clinical workflow differences that were not captured in the original volunteer-based validation studies.[23,25] If the Morse model is implemented—particularly where its demographic breadth is advantageous in pediatric or morbidly obese patients—hard infusion-rate caps must be manually programmed into the pump to prevent cardiovascular toxicity.[24,25] In practice (Figure 1), TCI should be initiated conservatively (Ce target 0.6–0.9 ng/mL for moderate sedation), with continuous hemodynamic monitoring and proactive Ce upward titration anticipated before procedural stimulation.[5,27] Broader multicenter validation of dexmedetomidine TCI across diverse procedural contexts remains an important unmet research need.

Dosing Strategies – Ranges, Administration Rates and Hemodynamic Tolerance

The literature (Table 2) and Figure 2 encompasses bolus doses ranging from 0.05 to 3 μg/kg, administered over intervals spanning a rapid 5-second injection to a 30-minute loading infusion, reflecting the diverse procedural contexts and patient populations in which DEX bolus sedation has been studied.[3,4] This variability reflects differences in clinical context, procedural urgency, and tolerance for hemodynamic perturbation. For maintenance of stable hemodynamics, lower infusion rates (eg., 0.1–0.5 μg/kg/hr) are often utilized, whereas an initial bolus of approximately 0.25 is preferred for blunting sympathetic responses during general anesthesia induction.[4] For adult procedural sedation, bolus doses of 0.25–0.5 μg/kg administered over 10 minutes are well-supported by evidence, achieving reliable sedation with acceptable hemodynamic effects.[12] Higher doses (1–2 μg/kg) are frequently employed in pediatric imaging sedation, with success rates exceeding 90% at bolus doses of 2 μg/kg over 10 minutes.[28] Lockout intervals of 1–3 minutes in patient-controlled sedation (PCS) systems have been shown to confer rapid onset with minimal adverse events in dental procedural sedation.[29]

A critical determinant of hemodynamic tolerability is administration rate. Rapid bolus injection (over 5 seconds) yields higher peak plasma concentrations that trigger the biphasic cardiovascular response more prominently—initial hypertension from peripheral vasoconstriction followed by dose-dependent bradycardia and hypotension. Slower administration over 10–30 minutes attenuates the peak concentration, substantially mitigating hemodynamic perturbations while achieving equivalent sedation depth.[5] Xia et al[31] demonstrated that 30-minute loading infusion produced significantly lower rates of respiratory and hemodynamic adverse events compared to 15-minute infusion. Similarly, Siddappa and Kamath[33] found that bolus administration was associated with greater hemodynamic variability than equivalent-dose continuous infusion in patients undergoing ENT surgeries. In elderly patients, reduced clearance attributable to declining hepatic function supports reduced loading doses (0.3–0.5 μg/kg) and slower infusion rates to mitigate the enhanced risk of bradycardia and hypotension.[34,35] The clinical implication is that when procedural urgency permits, the 10–30-minute infusion protocol for initial loading is preferred over rapid bolus delivery. Conversely, in settings where rapid sedation onset is essential (eg., emergency department procedural sedation), carefully titrated rapid bolus with appropriate monitoring and resuscitation preparedness is feasible.

Table 2 Summary of Representative Bolus Dosing Regimens Across Clinical Contexts

Study	Study Design	Population	Bolus Dose	Rate	Clinical Context	Key Finding
Rhee et al[29]	RCT	Adult	0.05–0.2 μg/kg	Rapid bolus (PCS)	Dental scaling	Effective PCS; minimal adverse effects
Chen et al[30]	Double-blind RCT	Pediatric	0.25–1.0 μg/kg	Rapid bolus	Post-anesthesia agitation	0.75–1.0 μg/kg reduces emergence agitation
Ahmed et al[28]	Retrospective study	Pediatric	2 μg/kg followed by 1 μg/kg/hr infusion	Over 10 min	Pediatric MRI	Effective sole agent; 3.9% bradycardia
Wang et al[4]	Prospective dose-finding	Adult	0.1–0.3 μg/kg	—	General anesthesia	ED50 ~0.25–0.28 μg/kg; stable hemodynamics
Dawes et al[20]	Prospective dose-finding	Pediatric	~0.49 μg/kg	Over 5 sec rapid bolus	Intraoperative	ED50 established; HR<60 up to 71%; no severe events
Xia et al[31]	RCT	Adult	1 μg/kg	15 or 30 min	Plastic surgery	30-min infusion preferred for hemodynamic stability
Inagaki et al[32]	Prospective Phase III RCT	Adult	0.5 or 1.0 μg/kg	Over 10 min	Procedural sedation	Well-tolerated; reduced rescue propofol need

Abbreviations: RCT, randomized controlled trial; PCS, patient-controlled sedation; ED50, median effective dose; MRI, magnetic resonance imaging.

https://doi.org/10.2147/DDDT.S606156



Figure 2 Dexmedetomidine dosing algorithm by population and clinical context. All doses assume intravenous administration unless otherwise specified. Doses should be individualized based on clinical response and hemodynamic tolerance. Section I presents adult dosing for procedural sedation (0.25–0.5 μg/kg), ICU sedation (load 0.5–1.0 μg/kg; maintenance 0.2–0.7 μg/kg/h), and general anesthesia adjunction (ED_{50} ≈ 0.25–0.28 μg/kg). Section II presents pediatric dosing for procedural/imaging sedation (1–2 μg/kg), intraoperative rapid bolus (ED_{50} ≈ 0.49 μg/kg), and emergence agitation prophylaxis (0.75–1.0 μg/kg). Section III details special population adjustments for elderly, obese, and neonatal patients. See Table 2 for source study details.

It should be acknowledged that the wide variability in study designs, populations, procedural contexts, and outcome definitions across the studies summarized above limits the direct comparability of dosing recommendations, and clinicians should interpret these data as informative ranges rather than prescriptive protocols.

Clinical Applications

ICU Sedation and Mechanical Ventilation

In the ICU setting, DEX has been increasingly adopted as a sedative option for mechanically ventilated patients. Several multicenter trials have reported associations between DEX use and lower delirium incidence compared with midazolam and lorazepam, although the evidence is derived from heterogeneous study designs with varying delirium assessment methodologies. Comparative data suggest that DEX may reduce delirium incidence (from approximately 37% to 14% in selected trials),[36] have been associated with shorter mechanical ventilation duration (median 21.9 versus 44.3 hours),[37] and may reduce ICU length of stay by a mean of 1.26 days.[6] In a nonrandomized controlled trial, Carrasco et al[38] reported that DEX was associated with a higher proportion of time at target sedation compared with haloperidol (92.7% vs 59.3%), although the absence of randomization and blinding limits the strength of this comparison. For ICU applications, DEX is typically administered as a continuous infusion with or without a loading bolus rather than as intermittent bolus dosing. A loading dose of 0.5–1.0 μg/kg over 10–20 minutes, followed by maintenance infusion at 0.2–0.7 μg/kg/h, is the standard regimen. Bradycardia (incidence 11.4–19.0%) and hypotension (20–28.6%) require vigilant monitoring[36,39] and atropine or vasopressor support should be immediately available. Notably, DEX pharmacokinetic variability is particularly pronounced in ICU patients with hemodynamic instability and multiorgan dysfunction,[40] necessitating individualized dose titration guided by clinical response and validated sedation scales. Venn et al[41] and Martin et al[42] established the foundational evidence for DEX's role in postsurgical ICU sedation. Albadi et al[43] conducted a bibliometric analysis synthesizing a decade of global research on dexmedetomidine for ICU agitation and delirium, utilizing co-citation networks to map critical clusters focused on sedation depth, comparative efficacy, and

https://doi.org/10.2147/DDDT.S606156

delirium prevention. To further enhance patient outcomes, the 4D trial reported a median reduction of agitation by approximately 1 h in hyperactive delirious non-intubated ICU patients.[44]

Pediatric Procedural Sedation

Pediatric procedural sedation represents one of the most extensively studied applications of DEX bolus administration, with sedation success rates exceeding 90% in MRI and CT imaging.[45] Although propofol retains advantages in faster induction and recovery,[46,47] DEX's arousable sedation profile, less respiratory depression, and preservation of airway reflexes make it particularly valuable in spontaneously breathing children outside the operating room. Mahmoud and Mason[48] identified DEX as a pivotal agent for non-operating room procedural sedation—a projection borne out by the expanding evidence base reviewed herein. Comprehensive pediatric dosing regimens, procedural applications across imaging and cardiac contexts, combination strategies, age-specific pharmacokinetic considerations, and neurodevelopmental safety data are discussed in Neonates, Infants and Children.

Adult Procedural Sedation

In adult procedural sedation, DEX bolus dosing has been validated across dental treatments, endoscopic procedures, emergency department interventions, endovascular therapies, and regional anesthesia adjunction. Rhee et al[29] demonstrated that patient-controlled propofol sedation with DEX at bolus doses of 0.05–0.2 μg/kg and lockout intervals of 1–3 minutes is effective for dental scaling, offering rapid onset, patient satisfaction, and manageable hemodynamic effects. Inagaki et al[32] confirmed effective sedation for non-intubated patients undergoing local anesthesia-based procedures outside the ICU in a prospective randomized phase III trial. For endovascular stroke treatment, Nii et al[49] reported favorable outcomes with DEX plus pentazocine, providing adequate conscious sedation while maintaining neurological assessment capability. In endoscopic retrograde cholangiopancreatography, Lu et al[50] found DEX-remifentanil superior to midazolam-remifentanil for conscious sedation quality.

Adjuvant to General and Neuraxial Anesthesia

In the perioperative context, DEX functions primarily as an adjuvant agent that reduces requirements for primary anesthetic and analgesic agents. In laparoscopic surgery or abdominal surgery,[14] the administration of dexmedetomidine has been associated with reduced intraoperative and postoperative opioid consumption[51] and pain score. In one trial of abdominal surgery patients, the generalizability of this single-center finding requires confirmation in larger, multicenter studies.[52] As an adjuvant to regional anesthesia, DEX prolongs sensory blockade duration substantially. Addition of 3 or 5 μg DEX to spinal anesthesia extends sensory and motor block significantly.[53] In brachial plexus block, DEX shortens sensory block onset from 14.3 to 12.0 minutes and extends duration from 369 to 564 minutes through peripheral α2-receptor–mediated mechanisms.[54] Oguz et al[55] demonstrated that DEX-propofol sedoanalgesia achieves lower desaturation rates, higher satisfaction scores, and fewer respiratory adverse events compared with remifentanil-propofol in day-case surgical anesthesia.

Beyond its role as a systemic combination partner, DEX has been investigated as an adjuvant to regional and neuraxial anesthesia, where perineural and intrathecal co-administration confer block-enhancing and opioid-sparing benefits. Marhofer[56] reviewed the safety and efficiency of DEX as an adjuvant to local anesthetics, providing mechanistic context for both perineural contributions to its block-enhancing and analgesic-sparing effects in regional anesthesia. Tang et al[57] conducted a prospective dose-response study using the up-down sequential allocation method to compare the ED50 of intrathecal hyperbaric ropivacaine with and without DEX for cesarean section, demonstrating that intrathecal DEX co-administration reduced the ropivacaine ED50 from 11.1 mg to 9.1 mg and concurrently decreased postoperative shivering incidence.

It should be acknowledged that the clinical applications summarized above are derived from studies of variable design (RCTs, prospective dose-finding studies, and observational investigations), heterogeneous patient populations, and inconsistent outcome definitions. Clinicians should interpret these findings as informative dosing ranges rather than prescriptive protocols, and individualized clinical judgment remains essential.

Hemodynamic and Respiratory Safety Profile

Cardiovascular Effects

As introduced in Introduction and detailed in Dosing Strategies – Ranges, Administration Rates and Hemodynamic Tolerance, dose-dependent decreases in heart rate and mean arterial pressure are the most consistent and predictable pharmacodynamic effects of DEX bolus administration. The incidence of clinically defined bradycardia (heart rate < 60 bpm) varies from less than 5%[28] with a very slow bolus to 71%[20] following rapid 5-second bolus. Despite the frequency of bradycardia, pharmacological intervention (atropine, glycopyrrolate) is required in fewer than 5% of cases across most series, indicating that the degree of heart rate reduction is generally well-tolerated hemodynamically.[58] Hypotension occurs in approximately 30%[39] of patients, potentially necessitating rescue intervention.[59,60] Like bradycardia, hypotension is typically transient and self-limiting, rarely necessitating vasopressor support when appropriate monitoring is in place. Zhang et al[61] characterized dose-dependent heart rate and blood pressure effects in ICU patients across a range of DEX doses, confirming that higher doses produce more pronounced but still manageable cardiovascular changes. Grégoire et al[62] reported a 23% incidence of hypertension in the first 5 minutes after ketamine bolus administration that resolved without intervention in the context of DEX–ketamine combination sedation.

Respiratory Effects

A frequently cited advantage of DEX over propofol, midazolam, and opioids is its relatively minimal impact on respiratory function. Belleville et al[12] established in the seminal human volunteer study that intravenous DEX at doses up to 2 μg/kg produced only minor, transient decreases in ventilation without clinically significant hypoxemia. The mechanism—locus coeruleus–mediated sedation rather than GABA-ergic respiratory center depression—preserves hypercapnic and hypoxic ventilatory responses. Clinically, this translates to extremely low rates of oxygen desaturation (< 2% in most series) and apnea during sole-agent DEX sedation. Peng et al[63] demonstrated significantly lower rates of airway adverse events with DEX compared with propofol in pediatric cerebral angiography. Mason et al[64] reported no respiratory complications despite hemodynamic changes in pediatric CT sedation. Nagoshi et al[65] found that low-dose DEX adjunction to propofol infusion reduced the need for airway support maneuvers. These findings collectively support DEX's utility in spontaneously breathing patients, those with reactive airway disease, and settings in which anesthesia provider airway rescue is not immediately available.

Comparative Efficacy

Dexmedetomidine versus Propofol

Propofol represents the most frequent comparator agent in DEX trials. Across pediatric imaging and procedural sedation studies, propofol consistently achieves faster induction and shorter recovery times than DEX,[46,47] a pharmacokinetic advantage attributable to propofol's ultra-short context-sensitive half-time. However, DEX has been associated with more favorable hemodynamic stability, lower reported rates of respiratory depression and desaturation, and better preservation of airway reflexes. Ahmed et al[47] found that propofol had a less reliable respiratory profile with higher rates of oxygen desaturation, while Nagoshi et al[65] demonstrated that DEX adjunction to propofol infusion reduced propofol dose requirements and decreased the incidence of airway interventions. The clinical decision between DEX and propofol should be guided by procedure-specific requirements. In high-throughput settings requiring rapid patient turnover, propofol's shorter recovery time confers a practical advantage. In patients with respiratory vulnerabilities, obesity-related airway risk, or when preservation of neuromonitoring is critical, DEX's comparatively favorable respiratory profile (as discussed in Respiratory Effects) may justify the longer recovery time.

Dexmedetomidine versus Midazolam

Midazolam, a GABA-ergic benzodiazepine, has been directly compared with DEX in several randomized trials.[7,58] For ICU patients, several randomized trials have reported favorable outcomes with DEX compared to midazolam, including lower delirium incidence, shorter mechanical ventilation duration, and better maintenance of arousable sedation, although the consistency of these advantages varies across clinical contexts.[39] Lu et al[50] reported superior conscious sedation

quality with DEX-remifentanil compared to midazolam-remifentanil during ERCP. The opioid-sparing properties of DEX, its analgesic contribution, and the absence of paradoxical excitation distinguish it favorably from midazolam in most procedural sedation contexts. Ramaswamy and Parimala[66] compared two different DEX loading doses with midazolam-fentanyl for sedation in vitreoretinal surgery under peribulbar anesthesia, demonstrating that low-dose DEX provided more consistent sedation depth with a Ramsay score maintained around 3 and fewer episodes of oversedation and excessive hemodynamic fluctuation compared with the midazolam-fentanyl regimen.

Dexmedetomidine in Combination Regimens

Combination regimens represent a major theme in the DEX literature, driven by the recognition that multimodal sedation strategies can exploit complementary pharmacodynamic profiles to enhance efficacy while attenuating individual drug adverse effects. Three primary combination partners are well-studied: ketamine, propofol, and midazolam.

DEX–ketamine combinations are particularly compelling: ketamine's sympathomimetic properties counteract DEX-induced bradycardia, its bronchodilatory effects complement DEX's respiratory preservation, and its dissociative analgesia synergizes with DEX's central analgesic mechanisms. Grégoire et al[62] validated DEX–ketamine in emergency department procedural sedation in adults, reporting one brief apnea episode resolved with jaw thrust. Kothari et al[67] confirmed DEX–ketamine superiority over midazolam–ketamine for short surgical procedures, including longer time to rescue analgesia and lower postoperative nausea and vomiting. The DEX–ketamine combination has also been extensively studied in pediatric populations across cardiac imaging, neuromuscular biopsy, and cardiac catheterization contexts, with generally favorable but not uniformly superior outcomes compared with alternative regimens; these data are reviewed in Neonates, Infants and Children.

DEX–propofol combinations effectively leverage propofol's faster onset and recovery while DEX reduces propofol dose requirements and mitigates respiratory and hemodynamic depression. Nakagawa et al[68] showed that DEX loading followed by propofol infusion prevents the delayed recovery associated with DEX–midazolam combinations in dental sedation. Pediatric evidence supporting DEX–propofol adjunctive sedation, including absence of desaturation events in dental patients, is discussed in Neonates, Infants and Children.

Routes of Non-Intravenous Administration

Intranasal Administration

Intranasal DEX has gained traction as a premedication and sedation route in pediatric patients, capitalizing on the nasal mucosa's rich vascularity and avoiding the distress of IV placement. Bioavailability via the intranasal route is approximately 84%, with a time to peak effect of approximately 47 minutes[69]-longer than IV but often acceptable for imaging sedation contexts where adequate preparation time exists. Alotaibi[45] reviewed pediatric MRI and CT sedation with various DEX routes including intranasal delivery, reporting clinically acceptable onset and recovery times with a favorable adverse event profile. Comparative efficacy data between intranasal and IV administration remain limited, representing a recognized gap in the literature. Baier et al[70] demonstrated that intranasal DEX was an effective sedative for electroencephalography and auditory brain response testing in children, achieving adequate sedation depth with a minimal respiratory compromise profile, establishing its utility for neurophysiological diagnostic procedures in pediatric practice.

Buccal, Sublingual, Subcutaneous and Perineural Administration

Buccal and sublingual DEX delivery represent additional non-invasive options explored primarily in pediatric sedation research. These routes bypass first-pass hepatic metabolism for the sublingual component, providing faster onset than oral administration. However, bioavailability data are more variable than for the intranasal route, and direct head-to-head comparisons against IV or intranasal administration are scarce. Further pharmacokinetic characterization and randomized clinical trials are necessary before buccal or sublingual DEX can be broadly recommended for procedural sedation.

Subcutaneous DEX administration has been investigated as a practical alternative route in settings where intravenous access is challenging. Uusalo et al[71] characterized subcutaneous DEX pharmacokinetics in healthy volunteers,

demonstrating efficient systemic absorption with a bioavailability of approximately 81% and a more attenuated cardiovascular response compared with intravenous administration—a profile potentially advantageous in hemodynamically vulnerable patients. Andersen et al[72] conducted a paired, blinded, randomized trial in healthy volunteers to investigate whether DEX exerts a perineural mechanism of action when used as an adjuvant to ropivacaine in peripheral nerve block, providing important mechanistic evidence that informs its use in regional anesthesia adjunction.

Special Populations

Neonates, Infants and Children

Developmental Pharmacokinetic Foundations

Pediatric dosing requirements for dexmedetomidine generally exceed those of adults on a per-kilogram basis, a consequence of developmental pharmacokinetic differences including a proportionally larger volume of distribution and more rapid drug clearance relative to body surface area. These differences are most pronounced at the extremes of pediatric age. Neonatal clearance (0.87–2.65 L/kg/h)[73] is substantially lower than in older children and is inversely related to postmenstrual - age, mandating conservative dosing and meticulous titration in this vulnerable population. Greenberg et al[73] characterized population pharmacokinetics in infants and provided quantitative dosing guidance that has become a foundational reference for neonatal DEX administration. In older children, maturation of hepatic glucuronidation and hydroxylation pathways progressively increases clearance, such that school-age children may require weight-adjusted doses comparable to or exceeding adult regimens to achieve equivalent sedation depth.

Dose-Finding Evidence

Empirical dose-finding studies have established critical dosing anchors across the pediatric age spectrum. Dawes et al[20] determined an ED50 of approximately 0.49 μg/kg for rapid intraoperative bolus administration in children, with heart rate reductions of up to 30% and 71% of subjects developing HR <60 bpm, although no severe hemodynamic events requiring intervention occurred. For sole-agent sedation during pediatric MRI, bolus doses of 2 μg/kg administered over 10 minutes have been validated with sedation success rates exceeding 90% and a bradycardia incidence of 3.9%.[28,64] An important application of DEX bolus in the pediatric perioperative setting is prevention of emergence agitation following volatile anesthetic agents. Chen et al[30] demonstrated in a double-blind randomized trial that rapid bolus doses of 0.75–1.0 μg/kg most effectively reduced emergence agitation incidence following sevoflurane anesthesia, and Begum et al[74] confirmed that bolus administration was superior to equivalent-dose low-rate infusion for this indication with comparable safety profiles.

Procedural Sedation Applications

The breadth of pediatric procedural contexts in which DEX bolus sedation has been investigated continues to expand. In pediatric CT imaging, hemodynamic monitoring reveals modest heart rate and blood pressure decreases that generally require no intervention.[64] For cardiac catheterization, DEX supports sedation without the respiratory compromise associated with propofol, making it particularly suitable for children with congenital heart disease in whom hemodynamic stability is paramount.[75] In pediatric dentistry, Sago et al[76] reported a case in which effective sedation with combined DEX and midazolam, demonstrating that this combination achieved adequate procedural conditions. Miller et al[77] characterized the dosing and efficacy of intranasal DEX for pediatric transthoracic echocardiography, providing a practical dosing reference for this non-invasive route in a challenging imaging context. Bong et al[78] reported the successful use of DEX sedation combined with caudal anesthesia for inguinal hernia repair in infants, highlighting its utility in minimizing systemic analgesic requirements in the youngest surgical patients.

Combination Regimens in Pediatric Practice

Multimodal sedation strategies exploiting complementary pharmacodynamic profiles have been extensively studied in children. DEX–ketamine combinations are particularly well-suited to pediatric practice: ketamine's sympathomimetic properties counterbalance DEX-induced bradycardia, and its dissociative analgesia synergizes with DEX's central analgesic mechanisms. Kako et al[79] demonstrated safety and efficacy of DEX–ketamine sedation in high-risk pediatric

patients with Duchenne muscular dystrophy undergoing muscle biopsy, noting shorter recovery times with lower DEX dosing. Shokri et al[80] found DEX–ketamine superior to midazolam–ketamine for sedation of pediatric patients with tetralogy of Fallot undergoing cardiac CT, with a more favorable safety and complication profile. In pediatric cardiac catheterization, Ülgey et al[81] demonstrated that adding DEX to a ketamine–propofol combination reduced airway interventions and patient movement while shortening recovery time. However, the evidence is not uniformly favorable: Tosun et al[82] reported that a propofol–ketamine combination outperformed DEX–ketamine in spontaneously breathing children undergoing cardiac catheterization, as the latter was associated with suboptimal sedation depth and delayed emergence. For DEX–propofol combinations, Rehman et al[83] reported no desaturation events in pediatric dental patients receiving DEX as an adjunct to propofol infusion. A detailed discussion of combination regimen pharmacodynamics and adult applications is provided in Dexmedetomidine in Combination Regimens.

Neurodevelopmental Safety Considerations

A critical unresolved question for pediatric DEX use concerns long-term neurodevelopmental outcomes. Andropoulos[84] reviewed the potential effects of anesthetic agents on the developing brain, raising important considerations for the neurodevelopmental safety of sedatives—including DEX—in neonatal and infant populations. Although preclinical data suggest that DEX may confer neuroprotective properties relative to GABAergic agents, no prospective clinical studies have examined neurodevelopmental trajectories following early-life DEX exposure. This represents a high-priority research gap given the rapidly expanding use of DEX in neonates and infants, and prospective longitudinal investigation is warranted.

Non-intravenous administration routes, particularly intranasal delivery with approximately 84% bioavailability and a time to peak effect of approximately 47 minutes, offer practical non-invasive advantages in pediatric practice and are discussed in Intranasal Administration.

Patients With Cardiac or Respiratory Morbidities

The relatively preserved respiratory function associated with DEX may make it a preferable option for patients with obstructive sleep apnea, reactive airway disease, chronic obstructive pulmonary disease, and pulmonary hypertension. Najafi et al[85] specifically evaluated DEX deep sedation in infants and small children with respiratory morbidities, reporting satisfactory usability and safety that support its preferential use in this population over propofol or benzodiazepines. In patients with congenital heart disease or significant acquired cardiac pathology, DEX's hemodynamic stability profile—particularly the absence of myocardial depression—offers advantages over propofol. Munro et al[75] reported the initial experience with DEX for cardiac catheterization in children, noting maintenance of heart rate and blood pressure within 20% of baseline without airway obstruction. Kunisawa et al[86] described successful DEX administration as a sole agent for diagnostic cardiac catheterization in adults with congenital heart disease. The caveat remains that DEX's bradycardic effect may be poorly tolerated in patients with pre-existing sinus node dysfunction or who depend on elevated heart rate for cardiac output maintenance.

Obese Patients

Body weight, hepatic function, and cardiac output are the principal determinants of DEX pharmacokinetic variability. In morbidly obese patients, the volume of distribution is markedly increased (310 ± 63 L vs. 164 ± 41 L in normal-weight individuals) and clearance is reduced (0.47 ± 0.07 vs. 0.64 ± 0.09 L/h/kg),[87] necessitating weight-based dose adjustments to avoid drug accumulation. Dose calculations should be based on total body weight with careful monitoring for prolonged effect and hemodynamic sequelae. The ED95 for DEX in obese patients has been reported as 0.75 μg/kg, comparable to normal-weight patients (0.74 μg/kg),[87,88] but the elimination half-time is substantially prolonged, necessitating adjusted recovery expectations and more extended monitoring periods.

Monitoring and Assessment Standards

Standardized monitoring during DEX bolus sedation encompasses assessment of sedation depth, hemodynamic status, and respiratory function. Validated sedation scales include the Ramsay Sedation Scale (target 3–4 for procedural

sedation), the Richmond Agitation-Sedation Scale (RASS; target −1 to −2 in most procedural contexts), and the Observer's Assessment of Alertness/Sedation (OAA/S) scale. Bispectral index (BIS) values of 60–80 correspond to procedural sedation targets in adults. Continuous cardiac monitoring (ECG, pulse oximetry, non-invasive blood pressure) at minimum 3-minute intervals is standard during loading and at 5-minute intervals during maintenance. Capnography is strongly recommended in sedation settings where direct airway observation is limited. In ICU contexts, neurological assessment using RASS and Confusion Assessment Method for the ICU (CAM-ICU) should occur at least every 4 hours, with DEX dosing adjusted to maintain the minimum effective sedation depth consistent with patient comfort and procedure requirements. Laboratory monitoring of hepatic and renal function is indicated in patients receiving prolonged DEX infusions, given its hepatic metabolism and the impact of organ dysfunction on pharmacokinetics.

Frade-Mera et al[89] conducted a systematic evaluation of sedation and analgesia outcomes in mechanically ventilated critically ill patients, identifying key gaps in standardized monitoring practices and reinforcing the importance of validated assessment tools such as RASS and CAM-ICU in guiding DEX titration during ICU sedation.

Strengths and Limitations

Nonetheless, the literature harbors several significant limitations for future directions (Table 3). First, dosing regimen heterogeneity is profound: bolus doses span a 60-fold range, administration rates vary from seconds to 30 minutes, and lockout intervals in PCS systems are inconsistently defined. This heterogeneity precludes robust meta-analysis and universal dosing recommendations. Second, many of the cited studies were single-center investigations with a moderate to high risk of bias. Additionally, the lack of blinding in several comparator trials may have confounded the results, while small sample sizes (<50 patients) further limit statistical power and external validity. Third, retrospective designs in several key series reduce internal validity and capacity for causal inference. Fourth, reporting of adverse events is inconsistent—definitions of clinically significant bradycardia, hypotension, and respiratory depression vary across studies, hampering safety comparisons. Fifth, long-term safety data are virtually absent: neurological outcomes,

Table 3 Priority Research Gaps and Future Directions in Dexmedetomidine Sedation

Gap Area	Description	Proposed Research	Priority
Dosing standardization	Very high variation in reported bolus doses and administration rates	Large-scale RCTs defining optimal doses and lockout intervals by age and procedure	High
Pediatric PK/PD modeling	Lack of validated PK-PD models across pediatric age groups	Population PK modeling studies in neonates, infants, children, and adolescents	High
Combination regimen optimization	Unclear dosing ratios and timing for DEX-ketamine, DEX-propofol	Systematic dose-finding studies with safety and recovery profiling	High
Long-term safety	No data on neurodevelopmental or cognitive outcomes post-sedation in children and geriatric populations	Prospective longitudinal cohort studies assessing neurodevelopmental and cardiovascular outcomes	High
Route comparisons	Limited head-to-head data: IV vs. intranasal vs. buccal	Randomized crossover trials in pediatric procedural sedation	Medium
Emergency applications	Limited evidence in emergency department high-acuity procedures	Targeted RCTs in emergency procedural sedation for fragile patients	High
Recovery time reduction	Prolonged recovery vs. propofol limits utility in high-throughput settings	Investigation of adjunctive agents or modified protocols to shorten recovery	Medium
Adverse event standards	Inconsistent definitions impede safety comparisons	Consensus guidelines for standardized adverse event reporting	High
TCI optimization	Limited validation of TCI for DEX outside spinal anesthesia contexts	Multicenter trials of DEX TCI across procedural sedation settings	Medium

Abbreviations: DEX, dexmedetomidine; IV, intravenous; PD, pharmacodynamics; PK, pharmacokinetics; RCT, randomized controlled trial; TCI, target-controlled infusion.

https://doi.org/10.2147/DDDT.S606156

neurodevelopmental effects in children, and cardiovascular sequelae beyond the immediate procedural period are largely unexplored. Sixth, pharmacoeconomic analyses integrating drug cost, procedure time, recovery duration, and adverse event management costs are lacking, limiting evidence-based formulary decision-making.

Conclusion

The available evidence suggests that dexmedetomidine offers a generally favorable efficacy and safety profile across a range of procedural and critical care sedation contexts, although the certainty of these conclusions is tempered by considerable heterogeneity in study designs, dosing protocols, and outcome definitions. Its pharmacodynamic profile—arousable sedation, preservation of respiratory drive, sympatholysis, and analgesic properties—distinguishes it from most currently available sedative agents. Optimal bolus dosing typically ranges from 0.25 to 1.0 μg/kg in adults and 1–2 μg/kg in pediatric procedural sedation, with administration rate critically modulating hemodynamic tolerability. Bradycardia and hypotension, while common dose-dependent effects, are generally transient and manageable; respiratory depression is rare. Several comparative studies have reported favorable respiratory and hemodynamic profiles for DEX relative to propofol and midazolam, though the magnitude and consistency of these advantages vary across patient populations and procedural settings. Combination regimens with ketamine or propofol may offer synergistic benefits that merit systematic optimization through well-designed trials. In ICU settings, DEX has been associated with reduced delirium incidence and shorter mechanical ventilation duration in selected trials, though long-term outcome data remain largely unavailable. Alternative non-invasive administration routes (intranasal and buccal) represent promising options for pediatric practice, pending head-to-head comparative validation. The evidence base, while growing, is limited by dosing heterogeneity, predominantly small sample sizes, inconsistent adverse event definitions, and a near-complete absence of long-term neurodevelopmental and cardiovascular outcome data. Standardization of dosing protocols, adverse event definitions, and outcome measures is essential to enable robust meta-analysis and evidence-based guideline development. Future multicenter randomized trials focused on special populations, combination regimen optimization, and advanced delivery technologies such as TCI are needed to further refine the role of dexmedetomidine in modern procedural sedation practice.

Disclosure

Jyu-Shiou Ho, Shao-Chun Wu are co-senior authors for this study. The authors report no conflicts of interest in this work.

References

1. Shukry M, Miller JA. Update on dexmedetomidine: use in nonintubated patients requiring sedation for surgical procedures. *Ther Clin Risk Manag*. 2010;6:111–121. doi:10.2147/tcrm.s5374
2. Davy A, Fessler J, Fischler M, M LEG. Dexmedetomidine and general anesthesia: a narrative literature review of its major indications for use in adults undergoing non-cardiac surgery. *Minerva Anestesiol*. 2017;83(12):1294–1308. doi:10.23736/S0375-9393.17.12040-7
3. Xie J, Feng S, Qu Z. Adoption of dexmedetomidine in different doses at different timing in perioperative patients. *Biomed Res Int*. 2022;2022:4008941. doi:10.1155/2022/4008941
4. Wang CY, Chen F, Wu J, et al. The association of the optimal bolus of dexmedetomidine with its favourable haemodynamic outcomes in adult surgical patients under general anaesthesia. *Br J Clin Pharmacol*. 2020;86(1):85–92. doi:10.1111/bcp.14137
5. Colin PJ, Hannivoort LN, Eleveld DJ, et al. Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile. *Br J Anaesth*. 2017;119(2):211–220. doi:10.1093/bja/aex086
6. Cruickshank M, Henderson L, MacLennan G, et al. Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic review. *Health Technol Assess*. 2016;20(25):1–117. doi:10.3310/hta20250
7. Luney M, Holdsworth L, Hanaga A, et al. Effectiveness of drug interventions to prevent delirium after surgery for older adults: systematic review and network meta-analysis of randomised controlled trials. *BMJ*. 2026;392:e085539. doi:10.1136/bmj-2025-085539
8. Aantaa R. Assessment of the sedative effects of dexmedetomidine, an alpha 2-adrenoceptor agonist, with analysis of saccadic eye movements. *Pharmacol Toxicol*. 1991;68(5):394–398. doi:10.1111/j.1600-0773.1991.tb01259.x
9. Akeju O, Loggia ML, Catana C, et al. Disruption of thalamic functional connectivity is a neural correlate of dexmedetomidine-induced unconsciousness. *eLife*. 2014;3:e04499. doi:10.7554/eLife.04499
10. Weerink MAS, Struys M, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. *Clin Pharmacokinet*. 2017;56(8):893–913. doi:10.1007/s40262-017-0507-7
11. Mahmoud M, Ishman SL, McConnell K, et al. Upper airway reflexes are preserved during dexmedetomidine sedation in children with down syndrome and obstructive sleep apnea. *J Clin Sleep Med*. 2017;13(5):721–727. doi:10.5664/jcsm.6592
12. Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. *Anesthesiology*. 1992;77(6):1125–1133. doi:10.1097/00000542-199212000-00013

13. Li A, Yuen VM, Goulay-Dufay S, Kwok PC. Pharmacokinetics and pharmacodynamics of dexmedetomidine. *Drug Dev Ind Pharm*. 2016;42 (12):1917–1927. doi:10.1080/03639045.2016.1232727
14. Jessen Lundorf L, Korvenius Nedergaard H, Moller AM. Perioperative dexmedetomidine for acute pain after abdominal surgery in adults. *Cochrane Database Syst Rev*. 2016;2(2):CD010358. doi:10.1002/14651858.CD010358.pub2
15. Zhang X, Yan F, Feng J, et al. Dexmedetomidine inhibits inflammatory reaction in the hippocampus of septic rats by suppressing NF-kappaB pathway. *PLoS One*. 2018;13(5):e0196897. doi:10.1371/journal.pone.0196897
16. Rong H, Zhao Z, Feng J, et al. The effects of dexmedetomidine pretreatment on the pro- and anti-inflammation systems after spinal cord injury in rats. *Brain Behav Immun*. 2017;64:195–207. doi:10.1016/j.bbi.2017.03.006
17. Wang D, Xu X, Wu YG, Lyu L, Zhou ZW, Zhang JN. Dexmedetomidine attenuates traumatic brain injury: action pathway and mechanisms. *Neural Regen Res*. 2018;13(5):819–826. doi:10.4103/1673-5374.232529
18. Xiong B, Shi Q, Fang H. Dexmedetomidine alleviates postoperative cognitive dysfunction by inhibiting neuron excitation in aged rats. *Am J Transl Res*. 2016;8(1):70–80.
19. Choi JJ, Kim JY, Lee D, Chang YJ, Cho NR, Kwak HJ. Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 mug/kg. *BMC Anesthesiol*. 2016;16(1):20. doi:10.1186/s12871-016-0186-1
20. Dawes J, Myers D, Gorges M, Zhou G, Ansermino JM, Montgomery CJ. Identifying a rapid bolus dose of dexmedetomidine (ED50) with acceptable hemodynamic outcomes in children. *Paediatr Anaesth*. 2014;24(12):1260–1267. doi:10.1111/pan.12468
21. Kim KM, Seo KH, Lee JM, Park EY, Park J. Target-controlled infusion of dexmedetomidine effect-site concentration for sedation in patients undergoing spinal anaesthesia. *J Clin Pharm Ther*. 2020;45(2):347–353. doi:10.1111/jcpt.13085
22. Dyck JB, Maze M, Haack C, Azarnoff DL, Vuorilehto L, Shafer SL. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. *Anesthesiology*. 1993;78(5):821–828. doi:10.1097/00000542-199305000-00003
23. Hannivoort LN, Eleveld DJ, Proost JH, et al. Development of an optimized pharmacokinetic model of dexmedetomidine using target-controlled infusion in healthy volunteers. *Anesthesiology*. 2015;123(2):357–367. doi:10.1097/ALN.0000000000000740
24. Morse JD, Cortinez LI, Anderson BJ. A universal pharmacokinetic model for dexmedetomidine in children and adults. *J Clin Med*. 2020;9 (11):3480. doi:10.3390/jcm9113480
25. Comment on Morse Eleveld DJ, Colin PJ, Hannivoort LN, Absalom AR, Struys MMRF. A universal pharmacokinetic model for dexmedetomidine in children and adults. *J Clin Med*. 2021;10(14):3003. doi:10.3390/jcm10143003
26. Ding Y, Wang X, Li X, He J, Teng X, Chen G. Safety and adverse events associated with dexmedetomidine for sedation in adult ICU patients: a systematic review and meta-analysis. *Front Med (Lausanne)*. 2025;12:1677955. doi:10.3389/fmed.2025.1677955
27. Colin PJ, Hannivoort LN, Eleveld DJ, et al. Dexmedetomidine pharmacokinetic-pharmacodynamic modelling in healthy volunteers: 1. Influence of arousal on bispectral index and sedation. *Br J Anaesth*. 2017;119(2):200–210. doi:10.1093/bja/aex085
28. Ahmed SS, Unland T, Slaven JE, Nitu ME. High dose dexmedetomidine: effective as a sole agent sedation for children undergoing MRI. *Int J Pediatr*. 2015;2015:397372. doi:10.1155/2015/397372
29. Rhee SH, Kweon YS, Won DO, Lee SW, Seo KS. Identification of an effective and safe bolus dose and lockout time for patient-controlled sedation (PCS) using dexmedetomidine in dental treatments: a randomized clinical trial. *J Dent Anesth Pain Med*. 2024;24(1):19–35. doi:10.17245/jdapm.2024.24.1.19
30. Chen F, Wang C, Lu Y, Huang M, Fu Z. Efficacy of different doses of dexmedetomidine as a rapid bolus for children: a double-blind, prospective, randomized study. *BMC Anesthesiol*. 2018;18(1):103. doi:10.1186/s12871-018-0562-0
31. Xia W, Wang S, Wei L, et al. Comparison of the efficacy and safety of dexmedetomidine administered in two different modes under procedural sedation and analgesia in plastic surgery. *Front Surg*. 2022;9:836398. doi:10.3389/fsurg.2022.836398
32. Inagaki Y, Morita K, Ozaki M, et al. The efficacy and safety of dexmedetomidine for procedural sedation in patients receiving local anesthesia outside the intensive care unit: a prospective, double-blind, randomized clinical phase III trial in Japan. *Yonago Acta Med*. 2022;65(1):26–43. doi:10.33160/yam.2022.02.005
33. Siddappa P, Kamath SS. Comparing the efficacy of dexmedetomidine administered as an intravenous infusion and intravenous bolus on hemodynamic stability of patients undergoing ear, nose, and throat surgeries. *Ann Afr Med*. 2025;24(2):474–480. doi:10.4103/aam.aam_106_24
34. Ko KH, Jun IJ, Lee S, Lim Y, Yoo B, Kim KM. Effective dose of dexmedetomidine to induce adequate sedation in elderly patients under spinal anesthesia. *Korean J Anesthesiol*. 2015;68(6):575–580. doi:10.4097/kjae.2015.68.6.575
35. Lee CW, Kim M. Effects of preanesthetic dexmedetomidine on hemodynamic responses to endotracheal intubation in elderly patients undergoing treatment for hypertension: a randomized, double-blinded trial. *Korean J Anesthesiol*. 2017;70(1):39–45. doi:10.4097/kjae.2017.70.1.39
36. Li J, Dong C, Zhang H, et al. Study of prevention and control of delirium in ventilated patients by simulating blockage of circadian rhythm with sedative in intensive care unit. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. 2016;28(1):50–56. doi:10.3760/cma.j.issn.2095-4352.2016.01.010
37. Reade MC, Eastwood GM, Bellomo R, et al. Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial. *JAMA*. 2016;315(14):1460–1468. doi:10.1001/jama.2016.2707
38. Carrasco G, Baeza N, Cabre L, et al. Dexmedetomidine for the treatment of hyperactive delirium refractory to haloperidol in nonintubated icu patients: a nonrandomized controlled trial. *Crit Care Med*. 2016;44(7):1295–1306. doi:10.1097/CCM.0000000000001622
39. Song R, Li J, Dong C, Yang J. A study of using dexmedetomidine in ventilator bundle treatment in an ICU. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. 2015;27(10):836–840.
40. Smuszkiewicz P, Wiczling P, Ber J, et al. Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients. *J Pharmacokinet Pharmacodyn*. 2018;45(2):277–284. doi:10.1007/s10928-017-9564-7
41. Venn M, Newman J, Grounds M. A Phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. *Intensive Care Med*. 2003;29(2):201–207. doi:10.1007/s00134-002-1579-9
42. Martin E, Ramsay G, Mantz J, Sum-Ping ST. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. *J Intensive Care Med*. 2003;18(1):29–41. doi:10.1177/0885066602239122
43. Albadi NA, Hassan Madani OF, Alshukaili SM, AlRawahi SA, Nair A. Dexmedetomidine for managing delirium and agitation in patients admitted to intensive care units: a bibliometric analysis. *Cureus*. 2025;17(11):e96219. doi:10.7759/cureus.96219
44. Godet T, Louis C, Rieu B, et al. Dexmedetomidine for treatment of hyperactive delirium in non-intubated ICU patients: the 4D randomized clinical trial. *Intensive Care Med*. 2025;51(12):2305–2317. doi:10.1007/s00134-025-08135-1

45. Alotaibi NS. Pediatric sedation outside the operating room integrating dexmedetomidine for MRI and CT scan procedures: a systematic review. *Saudi J Anaesth*. 2024;18(4):540–544. doi:10.4103/sja.sja_236_24
46. Kamal K, Asthana U, Bansal T, Dureja J, Ahlawat G, Kapoor S. Evaluation of efficacy of dexmedetomidine versus propofol for sedation in children undergoing magnetic resonance imaging. *Saudi J Anaesth*. 2017;11(2):163–168. doi:10.4103/1658-354X.203014
47. Ahmed SS, Unland TL, Slaven JE, Nitu ME. Dexmedetomidine versus propofol: is one better than the other for mri sedation in children? *J Pediatr Intensive Care*. 2017;6(2):117–122. doi:10.1055/s-0036-1584683
48. Mahmoud M, Mason KP. A forecast of relevant pediatric sedation trends. *Curr Opin Anaesthesiol*. 2016;29(1):S56–67. doi:10.1097/ACO.0000000000000321
49. Nii K, Hanada H, Hiraoka F, Eto A, Mitsutake T, Tsutsumi M. Usefulness of consciousness sedation with dexmedetomidine and pentazocine during endovascular treatment for acute stroke. *Neurol Med Chir (Tokyo)*. 2018;58(2):79–84. doi:10.2176/nmc.oa.2017-0188
50. Lu Z, Li W, Chen H, Qian Y. Efficacy of a dexmedetomidine-remifentanil combination compared with a midazolam-remifentanil combination for conscious sedation during therapeutic endoscopic retrograde cholangio-pancreatography: a prospective, randomized, single-blinded preliminary trial. *Dig Dis Sci*. 2018;63(6):1633–1640. doi:10.1007/s10620-018-5034-3
51. Bielka K, Kuchyn I, Babych V, Martycshenko K, Inozemtsev O. Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic cholecystectomy: a randomized controlled study. *BMC Anesthesiol*. 2018;18(1):44. doi:10.1186/s12871-018-0508-6
52. Abdel-Ghaffar HS, Mohamed SA, Fares KM. Combined Intrathecal morphine and dexmedetomidine for postoperative analgesia in patients undergoing major abdominal cancer surgery. *Pain Med*. 2016;17(11):2109–2118. doi:10.1093/pm/pnw031
53. Bi YH, Cui XG, Zhang RQ, Song CY, Zhang YZ. Low dose of dexmedetomidine as an adjuvant to bupivacaine in cesarean surgery provides better intraoperative somato-visceral sensory block characteristics and postoperative analgesia. *Oncotarget*. 2017;8(38):63587–63595. doi:10.18632/oncotarget.18864
54. Bisui B, Samanta S, Ghoshmaulik S, Banerjee A, Ghosh TR, Sarkar S. Effect of locally administered dexmedetomidine as adjuvant to levobupivacaine in supraclavicular brachial plexus block: double-blind controlled study. *Anesth Essays Res*. 2017;11(4):981–986. doi:10.4103/aer.AER_55_17
55. Oguz AK, Soyalp C, Tuncdemir YE, Tekeli AE, Yuzkat N. Sedoanalgesia with dexmedetomidine in daily anesthesia practices: a prospective randomized controlled trial. *BMC Anesthesiol*. 2025;25(1):45. doi:10.1186/s12871-025-02918-1
56. Marhofer P, Brummett CM. Safety and efficiency of dexmedetomidine as adjuvant to local anesthetics. *Curr Opin Anaesthesiol*. 2016;29(5):632–637. doi:10.1097/ACO.0000000000000364
57. Tang Y, Yang M, Fu F, Huang X, Feng Y, Chen X. Comparison of the ED50 of intrathecal hyperbaric ropivacaine co-administered with or without intrathecal dexmedetomidine for cesarean section: a prospective, double-blinded, randomized dose-response trial using up-down sequential allocation method. *J Clin Anesth*. 2020;62:109725. doi:10.1016/j.jclinane.2020.109725
58. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. *JAMA*. 2009;301(5):489–499. doi:10.1001/jama.2009.56
59. Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. *Ann Pharmacother*. 2007;41(2):245–252. doi:10.1345/aph.1H314
60. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. *Anesthesiology*. 2000;93(2):382–394. doi:10.1097/00000542-200008000-00016
61. Zhang X, Wang R, Lu J, et al. Effects of different doses of dexmedetomidine on heart rate and blood pressure in intensive care unit patients. *Exp Ther Med*. 2016;11(1):360–366. doi:10.3892/etm.2015.2872
62. Gregoire C, De Kock M, Henrie J, et al. Procedural sedation with dexmedetomidine in combination with ketamine in the emergency department. *J Emerg Med*. 2022;63(2):283–289. doi:10.1016/j.jemermed.2022.01.017
63. Peng K, Li J, Ji FH, Li Z. Dexmedetomidine compared with propofol for pediatric sedation during cerebral angiography. *J Res Med Sci*. 2014;19(6):549–554.
64. Mason KP, Zgleszewski SE, Prescilla R, Fontaine PJ, Zurakowski D. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. *Paediatr Anaesth*. 2008;18(5):393–402. doi:10.1111/j.1460-9592.2008.02451.x
65. Nagoshi M, Reddy S, Bell M, et al. Low-dose dexmedetomidine as an adjuvant to propofol infusion for children in MRI: a double-cohort study. *Paediatr Anaesth*. 2018;28(7):639–646. doi:10.1111/pan.13400
66. Ramaswamy SS, Parimala B. Comparative evaluation of two different loading doses of dexmedetomidine with midazolam-fentanyl for sedation in vitreoretinal surgery under peribulbar anaesthesia. *Indian J Anaesth*. 2016;60(2):89–93. doi:10.4103/0019-5049.176277
67. Kothari D, Sunny SA, Bansal A. Comparison of intravenous ketamine hydrochloride plus dexmedetomidine hydrochloride and ketamine hydrochloride plus midazolam hydrochloride in procedural sedation for short surgical procedures: a prospective randomized double-blind study. *Asian J Med Sci*. 2023;14(1):32–38. doi:10.71152/ajms.v14i1.3794
68. Nakagawa H, Hanamoto H, Kozu F, et al. Initial loading of dexmedetomidine and continuous propofol sedation for prevention of delayed recovery. *J Am Dent Assoc*. 2023;154(11):1008–1018.e2. doi:10.1016/j.adaj.2023.08.003
69. Miller JW, Balyan R, Dong M, et al. Does intranasal dexmedetomidine provide adequate plasma concentrations for sedation in children: a pharmacokinetic study. *Br J Anaesth*. 2018;120(5):1056–1065. doi:10.1016/j.bja.2018.01.035
70. Baier NM, Mendez SS, Kimm D, Velazquez AE, Schroeder AR. Intranasal dexmedetomidine: an effective sedative agent for electroencephalogram and auditory brain response testing. *Paediatr Anaesth*. 2016;26(3):280–285. doi:10.1111/pan.12851
71. Uusalo P, Al-Ramahi D, Tilli I, Aantaa RA, Scheinin M, Saari TI. Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. *Eur J Clin Pharmacol*. 2018;74(8):1047–1054. doi:10.1007/s00228-018-2461-1
72. Andersen JH, Grevstad U, Siegel H, Dahl JB, Mathiesen O, Jaeger P. Does dexmedetomidine have a perineural mechanism of action when used as an adjuvant to ropivacaine?: a paired, blinded, randomized trial in healthy volunteers. *Anesthesiology*. 2017;126(1):66–73. doi:10.1097/ALN.0000000000001429
73. Greenberg RG, Wu H, Laughon M, et al. Population Pharmacokinetics of Dexmedetomidine in Infants. *J Clin Pharmacol*. 2017;57(9):1174–1182. doi:10.1002/jcph.904
74. Begum U, Singh PR, Naithani B, Singh V, Singh GP, Tiwari T. Dexmedetomidine as bolus or low-dose infusion for the prevention of emergence agitation with sevoflurane anesthesia in pediatric patients. *Anesth Essays Res*. 2019;13(1):57–62. doi:10.4103/aer.AER_177_18

75. Munro HM, Tirotta CF, Felix DE, et al. Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children. *Paediatr Anaesth*. 2007;17(2):109–112. doi:10.1111/j.1460-9592.2006.02031.x
76. Sago T, Shiiba S, Ando E, et al. Sedation with a combination of dexmedetomidine and midazolam for pediatric dental surgery. *Anesth Prog*. 2018;65(2):124–126. doi:10.2344/anpr-65-03-14
77. Miller JW, Divanovic AA, Hossain MM, Mahmoud MA, Loepke AW. Dosing and efficacy of intranasal dexmedetomidine sedation for pediatric transthoracic echocardiography: a retrospective study. *Can J Anaesth*. 2016;63(7):834–841. doi:10.1007/s12630-016-0617-y.
78. Bong CL, Yeo AS, Fabila T, Tan JS. A pilot study of dexmedetomidine sedation and caudal anesthesia for inguinal hernia repair in infants. *Paediatr Anaesth*. 2016;26(6):621–627. doi:10.1111/pan.12907
79. Kako H, Corridore M, Kean J, Mendell JR, Flanigan KM, Tobias JD. Dexmedetomidine and ketamine sedation for muscle biopsies in patients with Duchenne muscular dystrophy. *Paediatr Anaesth*. 2014;24(8):851–856. doi:10.1111/pan.12387
80. Shokri H, Kasem AA, Ali I. Dexmedetomidine-ketamine sedation among pediatric patients with Fallot tetralogy undergoing cardiac multislice spiral computed tomography. *Egypt J Cardiothorac Anesth*. 2020;14(1):13–19. doi:10.4103/ejca.ejca_2_20
81. Ulgey A, Aksu R, Bicer C, et al. Is the addition of dexmedetomidine to a ketamine-propofol combination in pediatric cardiac catheterization sedation useful? *Pediatr Cardiol*. 2012;33(5):770–774. doi:10.1007/s00246-012-0211-1
82. Tosun Z, Akin A, Guler G, Esmaoglu A, Boyaci A. Dexmedetomidine-ketamine and propofol-ketamine combinations for anesthesia in spontaneously breathing pediatric patients undergoing cardiac catheterization. *J Cardiothorac Vasc Anesth*. 2006;20(4):515–519. doi:10.1053/j.jvca.2005.07.018
83. Rehman F, Goyal A, Gauba K, Jain K, Kapur A. Safety and efficacy of IV dexmedetomidine as an adjunct to propofol to sedate anxious and uncooperative pediatric dental patients: a randomized controlled trial. *J Clin Pediatr Dent*. 2021;45(6):428–432. doi:10.17796/1053-4625-45.6.10
84. Andropoulos DB. Effect of anesthesia on the developing brain: infant and fetus. *Fetal Diagn Ther*. 2018;43(1):1–11. doi:10.1159/000475928
85. Najafi N, Veyckemans F, Van de Velde A, Poelaert J. Usability of dexmedetomidine for deep sedation in infants and small children with respiratory morbidities. *Acta Anaesthesiol Scand*. 2016;60(7):865–873. doi:10.1111/aas.12715
86. Kunisawa T, Kurosawa A, Hayashi D, Takahashi K, Kishi M, Iwasaki H. Administration of dexmedetomidine alone during diagnostic cardiac catheterization in adults with congenital heart disease: two case reports. *J Anesth*. 2011;25(4):599–602. doi:10.1007/s00540-011-1174-8
87. Xu B, Zhou D, Ren L, Shulman S, Zhang X, Xiong M. Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. *J Anesth*. 2017;31(6):813–820. doi:10.1007/s00540-017-2399-y
88. Wu B, Shan J, Zhou Q, Wang L. Determination of the ED95 of a single bolus dose of dexmedetomidine for adequate sedation in obese or nonobese children and adolescents. *Br J Anaesth*. 2021;126(3):684–691. doi:10.1016/j.bja.2020.11.037
89. Frade-Mera MJ, Regueiro-Diaz N, Diaz-Castellano L, et al. A first step towards safer sedation and analgesia: a systematic evaluation of outcomes and level of sedation and analgesia in the mechanically ventilated critically ill patient. *Enferm Intensiva*. 2016;27(4):155–167. doi:10.1016/j.enfi.2015.10.002